AP2 associated kinase 1 inhibitors and uses thereof

A compound of Formula (IA′-3):

• or pharmaceutically acceptable salt, deuterated form, or stereoisomer thereof,
• wherein:
• Rb, Rc, and Rd are each independently H, halogen, C1-6 alkyl, —OH, —O—(C1-6 alkyl), —NH2, —NH—(C1-6 alkyl), or —NH—(C1-6 alkyl)2;
• R3 is H, halogen, C1-6 alkyl, —CN, —C(O)NH2, —C(O)OEt, or —C(O)OH;
• each R4 is independently halogen, OH, O—C1-6 alkyl, O—C1-6 haloalkyl, O-cycloalkyl, O-heterocyclyl, O—(C1-5 alkylene)-cycloalkyl, O—(C1-5 alkylene)-heterocyclyl, —NH—(C1-6 alkyl), —N(C1-6 alkyl)2, —NH-(cycloalkyl), or —NH-(heterocyclyl);
• each R5 is independently H, halogen, C1-6 alkyl, C1-6 heteroalkyl, O—C1-6 alkyl, C1-5 alkylene-cycloalkyl, or C1-5 alkylene-heterocyclyl, or two R5 form an oxo;
• R6 is H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
• R7 is H, C1-6 alkyl, C1-5 alkylene-OH, C1-5 alkylene-O—(C1-6 alkyl), C1-5 alkylene-O—CH2Ph, C1-5 alkylene-NH2, C1-5 alkylene-NH—(C1-6 alkyl), C1-3 alkylene-N(C1-6 alkyl)2, C1-5 alkylene-NH—(CH2Ph), C1-5 alkylene-C(O)—NH2, C1-5 alkylene-C(O)—NH—(C1-6 alkyl), C1-5 alkylene-C(O)—N(C1-6 alkyl)2, or 4- to 8-membered heterocyclyl;
• m is 0, 1, 2, or 3;
• and
• n is 0, 1, or 2.